文献速递神经头颈MR

通过常规MR成像与临床特征区分垂体转移瘤与垂体神经内分泌肿瘤

Distinguishing Pituitary Metastasis and Pituitary Neuroendocrine Tumors through Conventional MR Imaging and Clinical Features.
PubMed 文献 · AJNR Am J Neuroradiol · 2024-08-09

这项2中心回顾性研究分析了22例垂体转移瘤与74例垂体神经内分泌肿瘤的术前垂体MR及临床特征,年龄、性别、最大肿瘤大小两组间无显著分布差异。多因素logistic回归筛选出3个独立预测因子:复查MR上的快速生长、垂体柄肿块样或结节样增粗、癌症病史。基于这3个特征的模型AUC为0.987(95%CI 0.964-1),准确率97.9%(95%CI 92.7%-99.8%),敏感度95.5%(95%CI 77.2%-99.9%),特异度98.6%(95%CI 92.7%-100%),Brier评分0.025。

要点

  • 复查MR上快速生长、垂体柄肿块样或结节样增粗、癌症病史是区分垂体转移瘤与垂体神经内分泌肿瘤的3个独立预测因子。
  • 基于上述3个特征的模型AUC为0.987(95%CI 0.964-1),敏感度95.5%、特异度98.6%。
  • 本组垂体转移瘤中最常见的原发肿瘤为肺癌(9/22;41%),其次为乳腺癌(3/22;13.6%)与原发不明癌(3/22;13.6%)。

核心结论

  • 基于垂体柄肿块样或结节样增粗与复查MR快速生长两项常规MR特征,结合癌症病史这一临床变量,模型预测性能令人满意,可能有助于鉴别垂体转移瘤与垂体神经内分泌肿瘤;当两者鉴别困难时,本研究结果可能有助于诊断。

研究设计与样本

  • 2中心回顾性研究,自2024年1月起向前追溯,纳入22例垂体转移瘤与74例垂体神经内分泌肿瘤的术前垂体MR检查,排除无明确组织病理学诊断、MR前有垂体手术或放疗史、以及接受药物治疗的垂体神经内分泌肿瘤;由2名放射科医师系统评估13项常规MR特征,临床/流行病学特征包括年龄、性别、癌症病史与最大肿瘤大小,并记录原发癌来源;采用单因素与多因素logistic回归筛选变量、确定独立预测因子并建模,采用Cohen κ统计量或组内相关系数评估观察者间一致性。

关键影像表现/征象

  • 复查MR上快速生长被多因素logistic回归确定为独立预测因子。
  • 垂体柄肿块样或结节样增粗被多因素logistic回归确定为独立预测因子。
  • 癌症病史被多因素logistic回归确定为独立预测因子。
  • 年龄、性别与最大肿瘤大小在两组间无统计学显著分布差异。

诊断标准与关键数值

  • 基于快速生长、垂体柄肿块样或结节样增粗、癌症病史3项特征的模型AUC为0.987(95%CI 0.964-1)。
  • 该模型准确率为97.9%(95%CI 92.7%-99.8%),Brier评分为0.025。
  • 该模型敏感度为95.5%(95%CI 77.2%-99.9%),特异度为98.6%(95%CI 92.7%-100%)。

临床应用与阅片要点

  • 阅片时报告垂体柄是否呈肿块样或结节样增粗,并询问癌症病史,二者与复查MR快速生长共同构成独立预测因子。
  • 作者指出,当垂体转移瘤与垂体神经内分泌肿瘤鉴别困难时,本研究结果可能有助于诊断。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

BACKGROUND AND PURPOSE: Given their overlapping features, pituitary metastases frequently imitate pituitary neuroendocrine tumors in neuroimaging studies. This study aimed to distinguish pituitary metastases from pituitary neuroendocrine tumors on the basis of conventional MR imaging and clinical features as a practical approach.

MATERIALS AND METHODS: In this 2-center retrospective study, backward from January 2024, preoperative pituitary MR imaging examinations of 22 pituitary metastases and 74 pituitary neuroendocrine tumors were analyzed. Exclusion criteria were as follows: absence of a definitive histopathologic diagnosis, history of pituitary surgery or radiation therapy before MR imaging, and pituitary neuroendocrine tumors treated with medical therapy. Two radiologists systematically evaluated 13 conventional MR imaging features that have been reported more commonly as indicative of pituitary metastases and pituitary neuroendocrine tumors in the literature. Age, sex, history of cancer, and maximum tumor size constituted the clinical/epidemiologic features. The primary cancer origin for this study was also noted. Univariable and multivariable logistic regression was used for the selection of variables, determining independent predictors, and modeling. Interobserver agreement was evaluated for all imaging parameters using the Cohen κ statistic or intraclass correlation coefficient.

RESULTS: A total of 22 patients with pituitary metastases (8 women; mean age, 49.5 [SD, 13] years) and 74 patients with pituitary neuroendocrine tumors (36 women; mean age, 50.1 [SD, 11] years) were enrolled. There was no statistically significant distributional difference in age, sex, or maximum tumor size between the 2 groups. Lung cancer (9/22; 41%) was the most commonly reported primary tumor, followed by breast (3/22; 13.6%) and unknown cancer (3/22; 13.6%). Logistic regression revealed 3 independent predictors: rapid growth on control MR imaging, masslike or nodular expansion of the pituitary stalk, and a history of cancer. The model based on these 3 features achieved an area under the curve, accuracy, sensitivity, specificity, and Brier score of 0.987 (95% CI, 0.964-1), 97.9% (95% CI, 92.7%-99.8%), 95.5% (95% CI, 77.2%-99.9%), 98.6% (95% CI, 92.7%-100%), and 0.025, respectively.

CONCLUSIONS: Two conventional features based on pituitary MR imaging with the clinical variable of history of cancer had satisfying predictive performance, making them potential discriminators between pituitary metastases and pituitary neuroendocrine tumors. In cases in which differentiation between pituitary metastases and pituitary neuroendocrine tumors poses a challenge, the results of this study may help with the diagnosis.

来源:AJNR Am J Neuroradiol,查看原文。版权归原作者所有。

引用

  1. Yuzkan S, Erkan B, Dogukan FM, et al. Distinguishing Pituitary Metastasis and Pituitary Neuroendocrine Tumors through Conventional MR Imaging and Clinical Features. AJNR Am J Neuroradiol. 2024. PMID: 38871368. doi:10.3174/ajnr.A8302

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。